Navigation Links
BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
Date:10/28/2008

A Single Dose of Peramivir is Effective and Well-Tolerated at Both 300 mg and 600 mg Dose Levels

BIRMINGHAM, Ala., Oct. 28 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that a double-blind, placebo-controlled, Phase 2 study of intravenous (i.v.) peramivir, administered via a single dose injection in outpatients with acute, uncomplicated influenza, met its primary endpoint of time to alleviation of symptoms for both the 300 mg dose (p=0.0046) and 600 mg dose (p=0.0046). The study was sponsored by BioCryst's partner for peramivir, Shionogi & Co., Ltd.

The poster titled, "A Double-Blind, Placebo-Controlled Study of Intravenous Peramivir in Acute Influenza Patients" (Poster Session # 302: Respiratory Viruses I: Influenza and RSV) will be presented on Tuesday, October 28 from 12:15 p.m. - 1:15 p.m. Eastern Time in Hall C by Dr. Shigeru Kohno, Dean, Nagasaki University Graduate School of Medicine and Professor, Infection Immunology Department, Nagasaki University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.

"This Phase 2 study was a critical test of peramivir, which demonstrated for the first time that a single administration of this potent neuraminidase inhibitor can be effective in treating seasonal influenza," said Dr. William P. Sheridan, Chief Medical Officer of BioCryst. "The promising data in outpatient influenza highlights the potential of the compound as a novel and effective influenza therapy and we look forward to learning more about the clinical advantages of peramivir in the upcoming Shionogi-sponsored Phase 3 program."

The randomized, double-blind, placebo-controlled, Phase 2 study conducted in Japan enrolled 300 patients age 20 to 64, who
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
2. BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007
3. Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008
4. LCA-Vision Reports Third Quarter 2008 Financial Results
5. Universal Health Services, Inc. Reports 2008 Third Quarter Results
6. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
7. Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009
8. WellPoint Reports Third Quarter 2008 Results
9. Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80
10. Schering-Plough Reports Financial Results for Third Quarter of 2008
11. Quest Diagnostics Reports Growth in Revenue and Earnings for Third Quarter 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... U.S. Department of Health and Human Services (HHS) has ... Medical Center Seidman Cancer Center totaling $4.7 million to ... for patients with complex cancer. , Titled "Evidence-Conformant ... developed at UH to enhance care for adult cancer ... for high health care utilization. , "We ...
(Date:7/10/2014)... illness and even death are likely to result if ... Now, however, a team of researchers based at The ... order of infection, the bacteria Streptococcus pneumoniae ... case of the flu. , The researchers discovered ... a bacterial virulence factor, might protect macrophagesa type of ...
(Date:7/10/2014)... at sarcomas research group at the Bellvitge Biomedical Research ... have been tested in 19 patients a new therapeutic ... which indicate that the new treatment could stabilize the ... in the British Journal of Cancer ., ... and complex since there are several subtypes. It can ...
(Date:7/9/2014)... 2014 -- The World Health Organization recommends that youth ... to vigorous physical activity (MVPA) each day. Studies ... during school hours. Therefore, it stands to reason ... MVPA. In a new study scheduled for publication ... that time spent outdoors after school was positively associated ...
(Date:7/9/2014)... had an aneurysm, she figured an invasive brain surgery and ... said Wakulich, who is 56 years old and lives in ... Then I met Dr. Bernard Bendok who told me about ... was something I didn,t even know was an option." , ... to evaluate the safety and effectiveness of the Microvention Inc. ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Bacterial colonization prior to catching the flu may protect against severe illness 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:New type of stent could help some brain aneurysm patients 2
... Department of Defense (DOD) Breast Cancer Research Program (BCRP) ... Programs has awarded Silvia Formenti, MD, the Sandra and ... Radiation Oncology a $4.5 million Multi-Team Award to conduct ... offers tremendous promise for new therapeutic options for patients ...
... News) -- Certain gene mutations influence how likely people ... counter to experience, say researchers at Brown University. ... without gene mutations that affect the activity of the ... the prefrontal cortex and the striatum. The prefrontal ...
... TUESDAY, April 19 (HealthDay News) -- Nearly one-third of ... experience depression after the injury, a new study finds. ... existing research on blunt force trauma head injuries suffered ... "Any patient who has a traumatic brain injury ...
... release is available in German . ... consequences: Around first grade, the children start experiencing vision ... complete blindness. This is the first indication of a ... experience hallucinations, epileptic seizures, dementia and, finally, failure of ...
... glioma from chemoradiation may result in improved patient survival, ... Kimmel Cancer Center at Jefferson suggests. These ... the British Journal of Cancer . The ... such as fatigue and loss of short-term memory, that ...
... implants appear to be associated with a rare form of lymphoma, ... is caused by implants or to suggest an underlying mechanism for ... from the RAND Corporation. The study, published online by ... the disease takes a slow course and can be controlled by ...
Cached Medicine News:Health News:NYU Langone Medical Center awarded $4.5 million for breast cancer research 2Health News:Depression Common After Brain Injury 2Health News:Hope for children with rare genetic defect 2Health News:Hope for children with rare genetic defect 3Health News:Minimizing side effects from chemoradiation could help brain cancer patients live longer 2Health News:Study confirms link between breast implants and rare form of cancer 2Health News:Study confirms link between breast implants and rare form of cancer 3
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very ... King as its new Chief Executive Officer.  Mark was ... which he has overseen the company,s four facilities in ... Costa Rica.  Mr. King joined Tegra Medical in 2012 with ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
Clearview RSV is a simple, immunochromatographic assay to aid in the diagnosis of respiratory syncytial virus (RSV) infections in children less than 6 years and adults over age 60....
Clearview ULTRA FOB is a rapid, two-step immunochemical test for the detection of fecal occult blood....
... RTVue is an ultra-high speed, high resolution ... for retina imaging and analysis. ... Fourier-Domain Optical Coherence technology just emerging from ... The ultra-high speed and high ...
The Clearview hCG Test is for the rapid detection of human chorionic gonadotropin (hCG) in urine specimens. This test kit is used to obtain a visual, qualitative result and is intended for professio...
Medicine Products: